Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Guan, Haixia
ESPTTN, NCT06423235: Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules	Not yet recruiting	4	426	RoW	regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid, regular dose of placebo, 2x regular dose of placebo	Xintian Pharmaceutical	Thyroid Nodule	07/25	07/28
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.	Recruiting	3	108	Europe, Japan, US, RoW	Efgartigimod PH20 SC, Placebo PH20 SC	argenx	Thyroid Eye Disease	02/26	10/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Guan, Haixia
ESPTTN, NCT06423235: Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules	Not yet recruiting	4	426	RoW	regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid, regular dose of placebo, 2x regular dose of placebo	Xintian Pharmaceutical	Thyroid Nodule	07/25	07/28
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.	Recruiting	3	108	Europe, Japan, US, RoW	Efgartigimod PH20 SC, Placebo PH20 SC	argenx	Thyroid Eye Disease	02/26	10/27